Our objective was to identifymicroRNA (miRNA) expression patterns predictive of response to neoadjuvantchemotherapy (NAC) and/or anti-HER2 targeted therapies in patients beingtreated for early-stage HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.